Programme

Presentation synopsis:

Long-acting antiretroviral drugs

Long-acting (LA) formulations of antiretroviral drugs have the potential to revolutionise HIV prevention and treatment. These formulations are being studied for oral or systemic administration and aim at frequencies of doses as low as once or twice yearly. Although these treatments will provide benefits to all people living with HIV, they would be particularly important for patients suffering from pill fatigue or living in areas where the stigma of taking daily HIV pills is a concern. Data on the two injectable LA formulations of rilpivirine and cabotegravir and several others that have entered clinical development will be discussed.

Speaker biography:

Dr Marta Boffito, MD, PhD, FRCP, is a Consultant physician at Chelsea and Westminster Hospital, and Reader at Imperial College, London, United Kingdom.

 

She is the Clinical Research Lead of the Clinical Research Facility and HIV Service Lead at Chelsea and Westminster Hospital, where she runs numerous research projects and clinical trials, she consults on complex pharmacological issues, sees patients with HIV (she founded the first HIV over-50-years clinic in London, United Kingdom), and teaches HIV medicine and pharmacology at Imperial College London and in various National and International settings. She trained in Italy, the USA, and the United Kingdom and has a special interest in antiretroviral drug pharmacology: from prevention to treatment.

In these areas, she contributes to the educational, scientific, and guideline-formulation activities of national bodies including the British HIV Association. She has published over 150 peer-reviewed articles, editorials, and reviews. She has been involved in capacity building programmes for resource-limited settings (e.g. Uganda) and is an applicant on numerous successful collaborative grants.


Registration

Registration is open

Second Announcement

Take a look

Call for abstracts

Submissions are closed